Massachusetts General Hospital initiates oxytocin study for binge-eating disorder
Massachusetts General Hospital is conducting a study to evaluate intranasal oxytocin's effects on binge-eating disorder over 8 weeks, comparing it to placebo.
Asset / Drug
Drug and asset intelligence for Massachusetts with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.